y, 30 n-or

mg in
I.M. or NSAI
15 mg D-
I.V as induc
single ed
dose or asthm
doses a,
of 15 urtica
mg ria, or
I.M or other
I.V q6 allrgi
hours. c
Maxim reacti
um, 60 ons.
g  Use
daily. cauti
To ously
switch in
to P.O. patie
route, nts
10 mg with
P.O. histor
q4 to 6 y of
hours, pepti
p.r.n., c
up to ulcer
40 mg disea
daily. se,
Maxim hepat
um ic or
combi renal
ned dysfu
use of nctio

83
drug n,
not to hyper
exceed tensio
5 days. n, CV
disea
se, or
condi
tions
that
predi
spose
to
fluid
retent
ion.

84
 DRUG STUDY
Patient: X Medical diagnosis: Cellulitis in right lower extremity and Diabetes Melllitus type 2.
Address: Bitaog, Bansalan, Davao Su Attending physician: Dr. Sarno
Age: 79 yrs. Chief complaint: Wound Swelling at Right Leg
DATE GENER BRAND CLASSIFICATI ACTION INDICATION CONTRA- ROUTE & NURSING
IC NAME ON INDICATION DOSAGE RESPONSIBILITI
NAME ES
C Cleocin Lincosamide Inhibits  Systemic Systemic 300mg.  History:
L Phosphat antibiotic protein administ administration IVTT Allergy to
I e, Cleocin synthesis ration:  Contraindi q8 clindamycin,
N T, Cleocin in Serious cated with history of
J D Vaginal susceptibl infection allergy to asthma or
A A Ovules, e s caused clindamyci other
N M Clinda- bacteria, by n, history allergies,
U Y Derm causing suscepti of asthma allergy to
A C (CAN), cell ble or other tartrazine (in
R I Clindagel, death. strains allergies, 75- and 150-
Y N ClindaMax of tartrazine mg
, Clindets, anaerobe (in 75- and capsules);
3 Dalacin C s, 150-mg hepatic or
0, (CAN) streptoco capsules); renal
cci, hepatic or dysfunction;
2 staphylo renal lactation;
0 cocci, dysfunctio history of
1 pneumoc n; regional
0 occi; lactation. enteritis or
reserve  Use ulcerative
use for cautiously colitis;
penicilli in history of
n- newborns antibiotic
allergic and infants associated

85
84